Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.
Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.
Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3×5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney.
Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.
RiverVest leads $17 million investment in Adarza, brings on new president
ROCHESTER, NY and ST LOUIS, MO (Jan. 19, 2017) – Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing. Proceeds from the financing will be used to further expand production capacity in its St. Peters, MO manufacturing facility and fund final development …
ADARZA BIOSYSTEMS CLOSES ON $17 MILLION SERIES C FINANCING Read More »
ROCHESTER, N.Y. ST LOUIS, MO – Adarza BioSystems, Inc. a leading next generation innovator in label-free, multiplex assays announced today that it has closed a $5 M Series B financing. Proceeds from the financing will be used to expand production capacity in its St. Peters, MO manufacturing facility and launch its first immunoassay product consumable …
Adarza BioSystems Completes $5 M Series-B Closing Read More »
Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.
Adarza BioSystems, Inc. has executed an agreement with SunEdison Semiconductor to establish immunoassay consumable manufacturing facilities at its St. Peters, Missouri manufacturing site.
ROCHESTER, NY: Adarza BioSystems, Inc. a leading next generation innovator in label-free, multiplex assays announced today that it has closed the final tranche of its Series-A financing bringing the total Series-A financing amount to $6.8 million. Proceeds from the financing will be used to launch its first 100-plex immunoassay product consumable and instrument and accelerate …
Adarza BioSystems Completes $6.8M Series-A Financing Read More »
Life Science company expands presence to St. Louis ST. LOUIS, MO: BioGenerator recently led syndication of investment in Adarza BioSystems, Inc., to support further commercialization of the company’s immunoassay products. As part of the investment, Adarza will conduct its primary business and product development in St. Louis as well as its manufacturing activities. Adarza is …
BioGenerator Investment Helps Adarza BioSystems Establish Operations in St. Louis Read More »